US2844670A
(en)
|
1953-12-30 |
1958-07-22 |
Morris Michael Marks |
Rotary cam switches
|
US4288627A
(en)
|
1980-02-12 |
1981-09-08 |
Phillips Petroleum Company |
Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
US5120712A
(en)
|
1986-05-05 |
1992-06-09 |
The General Hospital Corporation |
Insulinotropic hormone
|
US5118666A
(en)
|
1986-05-05 |
1992-06-02 |
The General Hospital Corporation |
Insulinotropic hormone
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
EP0512042B1
(en)
|
1990-01-24 |
1998-04-08 |
BUCKLEY, Douglas I. |
Glp-1 analogs useful for diabetes treatment
|
ATE118545T1
(de)
|
1990-05-09 |
1995-03-15 |
Novo Nordisk As |
Eine ein endoglucanase enzym enthaltende zellulasezubereitung.
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
JP2961045B2
(ja)
|
1993-02-24 |
1999-10-12 |
日清製粉株式会社 |
腸管粘膜増強促進剤
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
AU7531094A
(en)
|
1993-08-24 |
1995-03-21 |
Novo Nordisk A/S |
Protracted glp-1
|
EP0717635B1
(en)
|
1993-09-07 |
2000-11-15 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
US6184208B1
(en)
|
1994-06-29 |
2001-02-06 |
Immunotech Developments Inc. |
Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
US5834428A
(en)
|
1995-04-14 |
1998-11-10 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
US6184201B1
(en)
|
1995-04-14 |
2001-02-06 |
Nps Allelix Corp. |
Intestinotrophic glucagon-like peptide-2 analogs
|
US5789379A
(en)
|
1995-04-14 |
1998-08-04 |
Allelix Biopharmaceutical Inc. |
Glucagon-like peptide-2 analogs
|
US5523449A
(en)
|
1995-05-17 |
1996-06-04 |
Bayer Corporation |
Process for preparing phosphorodichlorido-dithioates by reacting alkylmercaptans with phosphorus trichloride in the presence of sulfur
|
US5912229A
(en)
|
1996-03-01 |
1999-06-15 |
Novo Nordisk Als |
Use of a pharmaceutical composition comprising an appetite-suppressing peptide
|
DK0891378T3
(da)
|
1996-03-01 |
2003-01-06 |
Novo Nordisk As |
Anvendelse af farmaceutisk formulering omfattende et appetitundertrykkende peptid
|
DK1231219T3
(da)
|
1996-04-12 |
2010-12-20 |
Ontario Inc 1149336 |
GLucagon-lignende peptid-2 analoger
|
ATE316100T1
(de)
|
1996-06-05 |
2006-02-15 |
Roche Diagnostics Gmbh |
Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
US5994500A
(en)
|
1996-07-19 |
1999-11-30 |
1149336 Ontario Inc. |
Antagonists of intestinotrophic GLP-2 peptides
|
ATE417622T1
(de)
|
1996-08-08 |
2009-01-15 |
Amylin Pharmaceuticals Inc |
Regulation gastrointestinaler beweglichkeit
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
BRPI9711437B8
(pt)
|
1996-08-30 |
2021-05-25 |
Novo Nordisk As |
derivados de glp-1
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US20020025933A1
(en)
|
1996-08-30 |
2002-02-28 |
Knudsen Liselotte Bjerre |
GLP-2 derivatives
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6384016B1
(en)
|
1998-03-13 |
2002-05-07 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
DK0929567T3
(da)
|
1996-09-09 |
2005-06-27 |
Zealand Pharma As |
Forbedret fastfase-peptidsyntese og middel til anvendelse af en sådan syntese
|
KR20000036015A
(ko)
|
1996-09-09 |
2000-06-26 |
스타이니스 에바 |
알파-히드록시산 링커를 함유하는 펩티드 프로드럭
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
WO1998022577A1
(en)
|
1996-11-15 |
1998-05-28 |
Maria Grazia Masucci |
Fusion proteins having increased half-lives
|
US5952301A
(en)
|
1996-12-10 |
1999-09-14 |
1149336 Ontario Inc. |
Compositions and methods for enhancing intestinal function
|
AU739020B2
(en)
|
1997-01-07 |
2001-10-04 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the reduction of food intake
|
US6136784A
(en)
|
1997-01-08 |
2000-10-24 |
Amylin Pharmaceuticals, Inc. |
Amylin agonist pharmaceutical compositions containing insulin
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
WO1998035033A1
(en)
|
1997-02-05 |
1998-08-13 |
1149336 Ontario Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
CA2236519C
(en)
|
1997-05-02 |
2011-09-13 |
1149336 Ontario Inc. |
Methods of enhancing functioning of the large intestine
|
KR20010012321A
(ko)
|
1997-05-07 |
2001-02-15 |
막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. |
신규의 시스테인 유도체, 이의 제조 방법 및 이를 함유한약제
|
PT981362E
(pt)
|
1997-05-16 |
2004-03-31 |
Ontario Inc 1149336 |
Metodos de melhoramento do funcionamento do tracto gastrointestinal superior
|
US6051557A
(en)
|
1997-05-16 |
2000-04-18 |
1149336 Ontario Inc. |
Methods of enhancing functioning of the upper gastrointestinal tract
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
PT1019077E
(pt)
|
1997-08-08 |
2008-02-21 |
Amylin Pharmaceuticals Inc |
Novos compostos agonistas de exendina
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
BR9814189A
(pt)
|
1997-11-14 |
2000-10-03 |
Amylin Pharmaceuticals Inc |
"compostos agonistas da exendina"
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
MXPA00004670A
(es)
|
1997-11-14 |
2003-07-14 |
Amylin Pharmaceuticals Inc |
Compuestos agonistas de exendina novedosos.
|
WO1999029336A1
(en)
|
1997-12-05 |
1999-06-17 |
Eli Lilly And Company |
Glp-1 formulations
|
US6803357B1
(en)
|
1998-02-02 |
2004-10-12 |
New England Medical Center Hospitals, Inc. |
Method of regulating glucose metabolism, and reagents related thereto
|
JP4677095B2
(ja)
|
1998-02-13 |
2011-04-27 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
エキセンジンおよびglp−1の変力および利尿効果
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
AU2610899A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
NZ506839A
(en)
|
1998-03-09 |
2003-05-30 |
Zealand Pharma As |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
WO1999049788A1
(en)
|
1998-03-30 |
1999-10-07 |
Focus Surgery, Inc. |
Ablation system
|
WO1999058144A1
(en)
|
1998-05-11 |
1999-11-18 |
1149336 Ontario Inc. |
Methods of enhancing functioning of the large intestine
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
ES2553108T3
(es)
|
1998-08-10 |
2015-12-04 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diferenciación de células no productoras de insulina en células productoras de insulina mediante GLP-1 o exendina-4 y utilizaciones de las mismas
|
DE69926007T2
(de)
|
1998-10-07 |
2005-12-29 |
Medical College Of Georgia Research Institute, Inc. |
Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
KR20070051948A
(ko)
|
1999-01-14 |
2007-05-18 |
아밀린 파마슈티칼스, 인크. |
글루카곤 억제용 제약학적 조성물
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
CN100356978C
(zh)
|
1999-01-14 |
2007-12-26 |
安米林药品公司 |
新型exendin激动剂制剂及其给药方法
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
EP1956000B1
(en)
|
1999-03-17 |
2016-10-05 |
Novo Nordisk A/S |
Acylating agents useful for acylating peptides
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
EP1175443A1
(en)
|
1999-04-30 |
2002-01-30 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
ATE252601T1
(de)
|
1999-05-17 |
2003-11-15 |
Conjuchem Inc |
Lang wirkende insulinotrope peptide
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
US20030040478A1
(en)
|
1999-12-08 |
2003-02-27 |
Drucker Daniel J |
Chemotherapy treatment
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
WO2002022151A2
(en)
|
2000-09-18 |
2002-03-21 |
Osteometer Bio Tech A/S |
Use of glp-1 and flp-2 peptides for treatment of bone disorders
|
US7186683B2
(en)
|
2000-09-18 |
2007-03-06 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
MXPA02006118A
(es)
|
2000-10-20 |
2004-08-23 |
Amylin Pharmaceuticals Inc |
Tratamiento de la invernacion del miocardio y cardiopatia diabetica con un peptido glp-1.
|
WO2002066062A2
(en)
|
2001-02-01 |
2002-08-29 |
Drucker Daniel J |
Enhancement of glp-2 activity
|
CA2436399A1
(en)
|
2001-02-16 |
2002-08-29 |
Conjuchem Inc. |
Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
|
EP1542712A2
(en)
|
2001-06-01 |
2005-06-22 |
Eli Lilly And Company |
Glp-1 formulations with protracted time action
|
GB0121709D0
(en)
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
EP1837031B1
(en)
|
2002-06-07 |
2009-10-14 |
Waratah Pharmaceuticals, Inc. |
Compositions and methods for treating diabetes
|
DK1525219T3
(da)
|
2002-07-04 |
2009-09-07 |
Zealand Pharma As |
GLP-1 og fremgangsm der til behandling af diabetes
|
CA2500295A1
(en)
|
2002-10-02 |
2004-04-29 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
US7411039B2
(en)
|
2002-10-14 |
2008-08-12 |
Novo Nordisk A/S |
GLP-2 compounds, formulations, and uses thereof
|
US7192922B2
(en)
|
2002-11-19 |
2007-03-20 |
Allegheny-Singer Research Institute |
Method of treating left ventricular dysfunction
|
EP1664109B1
(en)
*
|
2003-08-21 |
2009-07-22 |
Novo Nordisk A/S |
Purification of glucagon-like peptides
|
CA2539253A1
(en)
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
US7623530B2
(en)
|
2003-11-20 |
2009-11-24 |
Nokia Corporation |
Indication of service flow termination by network control to policy decision function
|
CA2554458A1
(en)
|
2004-01-30 |
2005-08-11 |
Waratah Pharmaceuticals, Inc. |
The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
WO2005077072A2
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
WO2005082404A2
(en)
|
2004-02-27 |
2005-09-09 |
Novo Nordisk A/S |
Glp-2 derivatives modified by lipophilic substituents
|
CN101010339B
(zh)
*
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
DK1809318T3
(da)
|
2004-11-01 |
2013-09-08 |
Nps Pharma Inc |
Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
|
BRPI0610091B1
(pt)
|
2005-05-04 |
2021-08-03 |
Zealand Pharma A/S |
Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico
|
PE20061448A1
(es)
*
|
2005-05-26 |
2006-12-17 |
Bristol Myers Squibb Co |
Compuestos polipeptidos como moduladores del peptido 1 similar al glucagon humano
|
EP1767545B1
(en)
*
|
2005-09-22 |
2009-11-11 |
Biocompatibles UK Limited |
GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
|
WO2007095737A1
(en)
|
2006-02-21 |
2007-08-30 |
Waratah Pharmaceuticals Inc. |
Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
|
US7928058B2
(en)
|
2006-02-22 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
|
US8642727B2
(en)
|
2006-11-08 |
2014-02-04 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (GLP-2) analogues
|
WO2008071010A1
(en)
|
2006-12-12 |
2008-06-19 |
Waratah Pharmaceuticals Inc. |
Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
KR20150116465A
(ko)
|
2007-02-15 |
2015-10-15 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-항진물질
|
ATE520714T1
(de)
|
2007-06-15 |
2011-09-15 |
Zealand Pharma As |
Glucagonanaloga
|
GB2455553B
(en)
|
2007-12-14 |
2012-10-24 |
Nuaire Ltd |
Motor mounting assembly for an axial fan
|
KR20110039230A
(ko)
|
2008-06-17 |
2011-04-15 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
생리학적 pH 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
|
CN102282167B
(zh)
|
2008-12-15 |
2014-08-13 |
西兰制药公司 |
胰高血糖素类似物
|
ES2439499T3
(es)
*
|
2008-12-15 |
2014-01-23 |
Zealand Pharma A/S |
Análogos de glucagón
|
CA2747112A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
NZ593813A
(en)
|
2008-12-15 |
2013-02-22 |
Zealand Pharma As |
Glucagon analogues
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
NZ597981A
(en)
*
|
2009-07-13 |
2014-02-28 |
Zealand Pharma As |
Acylated glucagon analogues
|
WO2011084808A2
(en)
|
2009-12-21 |
2011-07-14 |
Amunix Operating Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
KR20120128129A
(ko)
|
2010-01-20 |
2012-11-26 |
질랜드 파마 에이/에스 |
심장 병태의 치료
|
EA023925B1
(ru)
|
2010-04-27 |
2016-07-29 |
Зилэнд Фарма А/С |
Пептидные конъюгаты агонистов рецептора glp-1 и их применение
|
WO2011143335A2
(en)
*
|
2010-05-11 |
2011-11-17 |
Nps Pharmaceuticals, Inc. |
Methods for treatment or prophylaxis of kidney or liver dysfunction
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
NZ604208A
(en)
*
|
2010-06-24 |
2014-10-31 |
Zealand Pharma As |
Glucagon analogues
|
EP2627770B1
(en)
*
|
2010-10-15 |
2017-06-28 |
Cornell University |
Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
|
US10471127B2
(en)
|
2011-05-18 |
2019-11-12 |
Mederis Diabetes, Llc |
Peptide pharmaceuticals for insulin resistance
|
JP6359972B2
(ja)
|
2011-11-03 |
2018-07-18 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1受容体アゴニストペプチドガストリンコンジュゲート
|
AP2014007797A0
(en)
*
|
2011-12-23 |
2014-07-31 |
Boehringer Ingelheim Int |
Glucagon analogues
|
EP2844670B1
(en)
|
2012-05-03 |
2017-12-06 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
MY176022A
(en)
|
2013-10-17 |
2020-07-21 |
Boehringer Ingelheim Int |
Acylated glucagon analogues
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
EP3065767B1
(en)
*
|
2013-11-06 |
2020-12-30 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
AU2014345570B2
(en)
|
2013-11-06 |
2019-01-24 |
Zealand Pharma A/S |
Glucagon-GLP-1-GIP triple agonist compounds
|
CA2965560A1
(en)
*
|
2014-10-31 |
2016-05-06 |
Gubra Aps |
Compositions and peptides having dual glp-1r and glp-2r agonist activity
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
DK3551651T3
(da)
|
2016-12-09 |
2024-05-13 |
Zealand Pharma As |
Acylerede glp-1/glp-2-dobbeltagonister
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
EP3551652B1
(en)
|
2016-12-09 |
2021-01-20 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|